1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Sluggish Copaxone Rival And Delay To Generic Advair Hurt Mylan

 
• By Dave Wallace

Mylan has blamed a sluggish uptake for its Copaxone rival and a delay in FDA approval of its generic version of Advair Diskus for the firm’s sales suffering a 4% drop and EBITDA falling by 8% in 2018.

Snail
Slower Than Expected Uptake For Glatiramer And A Delay To Wixela Inhub’s Approval Hit Mylan In 2018 • Source: Shutterstock

Lower-than-expected uptake for its generic version of Teva’s Copaxone (glatiramer acetate) and a delay to US Food and Drug Administration (FDA) approval of its rival to GlaxoSmithKline’s (GSK’s) Advair Diskus (fluticasone/salmeterol) threw a spanner in the works for Mylan in 2018, contributing to its sales falling by 4% to US$11.43 billion for the year and earnings before interest, tax, depreciation and amortization (EBITDA) falling by more than 8% to US$3.03 billion.

“We experienced lower than expected uptake of our generic Copaxone, even after reducing the price by more than 50%, which perfectly illustrates the current distorted financial incentives within the specialty pharmacy marketplace,” commented Mylan CEO Heather Bresch

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Viatris Awaits ‘Significant Rebound’ At Indore In 2026 After Painful Q1 Bite

 
• By Dean Rudge

Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.